Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort studyChristopher M. Clark, Daniel Skovronsky, Barry J. Bedell et al.|The Lancet Neurology|2012Cited by 846
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty yearsGerda G. Fillenbaum, Albert Heyman, Gerald van Belle et al.|Alzheimer s & Dementia|2008Cited by 491
Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal agingKeith A. Johnson, Reisa A. Sperling, Christopher Gidicsin et al.|Alzheimer s & Dementia|2013Cited by 265
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive declineP. Murali Doraiswamy, Reisa A. Sperling, Robert E. Coleman et al.|Neurology|2012Cited by 228
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiativeRosa Rademakers, Mike Hutton, Matt Baker et al.|The Lancet Neurology|2007Cited by 217